Sugi Predict

Sugi Predict / Compounds / SCHEMBL304435

SCHEMBL304435

SCHEMBL304435

Cc1cc2c(cc1-c1cc(C=C3NC(=O)SC3=O)ccc1OC(F)(F)F)C(C)(C)CCC2(C)C

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 15/20 0.56
▸ SCN9A Q15858 1/20 0.43
▸ CSNK2A2 P19784 1/20 0.41
▸ CLK1 P49759 1/20 0.41
▸ CSNK2B P67870 1/20 0.41
▸ CSNK2A1 P68400 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ DYRK2 Q92630 1/20 0.41
▸ DYRK1B Q9Y463 1/20 0.41
▸ PIM1 P11309 2/20 0.40
▸ PIM2 Q9P1W9 2/20 0.40
▸ ESRRA P11474 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304433 0.89 RXRA (0.69) RXRASCN9APIM1PIM2ESRRA
SCHEMBL1619112 0.89 RXRA (0.69) RXRASCN9APIM1PIM2ESRRA
SCHEMBL304434 0.89 RXRA (0.69) RXRASCN9APIM1PIM2ESRRA
SCHEMBL7462864 0.82 RXRA (0.59) RXRASCN9ACSNK2A1DYRK1APIM1
SCHEMBL7462867 0.82 RXRA (0.59) RXRASCN9ACSNK2A1DYRK1APIM1
SCHEMBL5484727 0.81 RXRA (0.52) RXRA
SCHEMBL6450433 0.80 RXRA (0.66) RXRASCN9APIM1PIM2ESRRA
SCHEMBL6450432 0.80 RXRA (0.66) RXRASCN9APIM1PIM2ESRRA
SCHEMBL14492768 0.80 RXRA (0.57) RXRASCN9ACSNK2A1DYRK1APIM1
SCHEMBL5484607 0.80 RXRA (0.57) RXRASCN9ACSNK2A1DYRK1APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604541-B2 Glucokinase activators and methods of using same BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-31 — — US disclosed
US-20190233449-A1 GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2019-08-01 — — US disclosed
EP-2850073-B1 PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2017-07-19 — — EP disclosed
US-9174965-B2 Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-03 — — US disclosed
EP-2566862-B1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-09-16 — — EP disclosed
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 — — US disclosed
US-20150133479-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2015-05-14 — — US disclosed
WO-2015061272-A1 ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 — — WO disclosed
EP-2556069-B1 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2015-04-01 — — EP disclosed
US-20150086504-A1 POLYMERIC MICROEMULSIONS JANSSEN PHARMACEUTICA NV (BE) 2015-03-26 — — US disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 — — US disclosed
WO-2009012277-A1 METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 — — WO disclosed
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-15 — — US disclosed
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2008-11-27 — — US disclosed
WO-2008137435-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-13 — — WO disclosed
WO-2008137436-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-13 — — WO disclosed
EP-1504047-B1 POLYMERIC MICROEMULSIONS JANSSEN PHARMACEUTICA NV (BE) 2007-12-12 — — EP disclosed
US-20060034797-A1 Polymeric micromulsions ETHICON INC. 2006-02-16 — — US disclosed
EP-1504047-A1 POLYMERIC MICROEMULSIONS JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-09 — — EP disclosed
WO-2003093344-A1 POLYMERIC MICROEMULSIONS JANSSEN PHARMACEUTICA N.V. (BE) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR139, GPR4 RXRA 460/4885SCN9A 434/4885CSNK2A2 2310/4885
US-10604541-B2 Glucokinase activators and methods of using same GCK, GCKR, GALK1 RXRA 1949/4885SCN9A 1687/4885CSNK2A2 689/4885
US-20150133479-A1 PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS GPR119, GPR180, GPR139 RXRA 517/4885SCN9A 904/4885CSNK2A2 1096/4885
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR6, GPR139 RXRA 448/4885SCN9A 515/4885CSNK2A2 2510/4885
US-20190233449-A1 GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCK, GCKR, GALK1 RXRA 1949/4885SCN9A 1687/4885CSNK2A2 689/4885
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 RXRA 361/4885SCN9A 1227/4885CSNK2A2 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.